AstraZeneca shares are trading higher after the company announced it entered into a strategic collaboration agreement with Abbisko Therapeutics to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer. The company and CSPC Pharmaceutical Group entered into an agreement to use the siRNA drug discovery platform to develop novel small nucleic acid drug candidates.